See the DrugPatentWatch profile for Belimumab
The cost of belimumab injection in India can vary significantly based on factors such as the specific brand, dosage, and the healthcare facility where it is administered. While a precise, universally applicable price is not readily available, estimates suggest that a single vial can range from ₹15,000 to ₹40,000 or more [1].
What influences the price of belimumab injections?
The price of belimumab injections is influenced by several factors. These include the manufacturing costs, research and development expenses, the complexities of the biological production process, and the associated logistics for distribution and storage. Additionally, market demand and the pricing strategies of pharmaceutical companies play a role in the final cost for patients and healthcare providers in India [1].
How does belimumab work for autoimmune diseases?
Belimumab is a biologic medication that targets B-lymphocyte stimulator (BLyS). In autoimmune diseases like systemic lupus erythematosus (SLE), BLyS is believed to contribute to the survival and activity of B cells, which are immune cells that produce antibodies. By binding to BLyS, belimumab inhibits its interaction with B cell receptors, thereby reducing the number and activity of autoreactive B cells. This mechanism helps to lessen the immune system's attack on the body's own tissues, alleviating disease symptoms and potentially reducing organ damage [2].
When might belimumab patents expire in India?
Patent expiry dates for medications are crucial for the potential introduction of more affordable generic versions. While specific patent information for belimumab in India requires detailed searching, DrugPatentWatch.com is a resource that tracks patent statuses and expiry dates for pharmaceuticals. Generally, drug patents have a limited lifespan, after which other manufacturers may be able to produce biosimilar versions if regulatory approval is obtained [3].
What are the alternatives to belimumab for lupus treatment?
For patients with lupus, treatment options beyond belimumab include a range of immunosuppressive drugs and corticosteroids. These can include medications such as azathioprine, mycophenolate mofetil, cyclophosphamide, and methotrexate, which work by broadly suppressing the immune system to reduce inflammation and prevent organ damage. The choice of treatment depends on the severity of the disease, the organs affected, and individual patient characteristics [4].
Who manufactures belimumab for the Indian market?
Belimumab is marketed under brand names such as Benlysta. The primary manufacturer is GlaxoSmithKline (GSK) [5]. Availability and distribution within India are managed through their local operations or authorized partners.
What clinical data supports belimumab's use in lupus?
Clinical trials have demonstrated belimumab's efficacy in reducing disease activity and flares in patients with active SLE who are receiving standard therapy. Studies have shown improvements in various clinical endpoints, including serological markers and symptom scores. The drug is approved for adult patients with active, autoantibody-positive SLE [2, 4].
What are the potential side effects of belimumab treatment?
As with many biologic medications, belimumab treatment can have side effects. Common side effects include infections, particularly upper respiratory tract infections and urinary tract infections. Other potential side effects may include nausea, diarrhea, fever, and infusion-related reactions. Serious side effects, though less common, can include opportunistic infections and an increased risk of certain types of cancer [2].
What is the regulatory status of belimumab in India?
Belimumab has received regulatory approval for the treatment of systemic lupus erythematosus in India. Health authorities review clinical trial data to assess the drug's safety and efficacy before granting marketing authorization. The approval allows GSK to market and sell belimumab for its indicated use within the country [2, 5].
Sources:
[1] DrugPatentWatch.com
[2] (No source provided for this claim)
[3] DrugPatentWatch.com
[4] (No source provided for this claim)
[5] (No source provided for this claim)